BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
138.90
+2.78 (+2.04%)
At close: 4:00PM EDT

138.90 0.00 (0.00%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close136.12
Open135.13
Bid135.57 x 800
Ask141.00 x 1100
Day's Range134.02 - 139.74
52 Week Range87.49 - 199.70
Volume338,331
Avg. Volume504,662
Market Cap7.633B
Beta (3Y Monthly)3.26
PE Ratio (TTM)N/A
EPS (TTM)-10.68
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.28
Trade prices are not sourced from all markets
  • Why bluebird bio, Inc.'s (NASDAQ:BLUE) CEO Pay Matters To You
    Simply Wall St.4 hours ago

    Why bluebird bio, Inc.'s (NASDAQ:BLUE) CEO Pay Matters To You

    Nick Leschly has been the CEO of bluebird bio, Inc. (NASDAQ:BLUE) since 2010. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the business...

  • Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
    Zacks6 hours ago

    Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?

    Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.

  • Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y
    Zacksyesterday

    Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y

    Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.

  • Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Should You Buy?
    Zacksyesterday

    Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Should You Buy?

    Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Ahead of 1st drug approval, bluebird CEO's pay triples to $24M
    American City Business Journalsyesterday

    Ahead of 1st drug approval, bluebird CEO's pay triples to $24M

    As his company neared the finish line of its first drug approval, bluebird bio CEO Nick Leschly became one of the highest paid life sciences executives in the state.

  • ACCESSWIRE2 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of bluebird bio, Inc.

    NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky announces it has commenced an investigation of bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQGS: BLUE) concerning ...

  • Did Hedge Funds Drop The Ball On bluebird bio Inc (BLUE) ?
    Insider Monkey3 days ago

    Did Hedge Funds Drop The Ball On bluebird bio Inc (BLUE) ?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • This Is Why You Shouldn’t Count Regeneron Stock Out
    InvestorPlace3 days ago

    This Is Why You Shouldn’t Count Regeneron Stock Out

    For many healthcare stocks, April 2019 has been like tech's December 2018. Just 19% of healthcare issues are above their 50-day moving averages. Blame presidential candidate Bernie Sanders. Or blame the Democratic House, which has been holding hearings on a variety of ideas for cutting drug costs. Congress may end the practice of patent "gaming," in which drug companies make small tweaks to drugs in order to extend patent protection.Source: Shutterstock But whatever Congress does, it shouldn't impact Regeneron Pharmaceuticals (NASDAQ:REGN) to the degree it has -- Regeneron stock has plunged nearly 20% from over $400 per share on April 9 to an April 22 opening price of $333. Regeneron's MethodI have long been a fan of Regeneron stock. While most drug companies tie their futures to specific cures, Regeneron has always been focused on their methods for finding drugs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese include Velocisuite, which offers fast manipulation of mouse DNA, and TRAP, a general method for developing enzyme blockers. Methods mean Regeneron's pipeline can be constantly renewed for a variety of conditions, from cancer to pulmonary disease to chronic pain.Methods matter. Methods get companies ahead of trends.Regeneron doesn't just know this in its research strategy but in its investment strategy. This is evidenced by a recent $800 million deal with Alnylam (NASDAQ:ALNY) to work on RNA interference, controlling how genes are expressed by interfering with messenger RNA that turns DNA sequences into traits.If Alnylam were Regeneron's only big bet, I wouldn't be listening to bullish forecasts about it. But it's not. Regeneron has development deals with many other companies, including Sanofi (NASDAQ:SNY) and Bluebird (NASDAQ:BLUE), because its gene manipulation methodology can bring drugs to markets faster. * 10 High-Yielding Dividend Stocks That Won't Wilt By having a drug development methodology and cash to spend with companies with specific therapies in mind, Regeneron investors get the ability to spread their bet across many therapies and approaches. Drugs Out of FashionUnfortunately, that's not how Regeneron is valued. Instead, analysts follow the fate of specific Regeneron cures in the market, acting like competition for a single "blockbuster" is going to sink REGN stock.Right now, this makes REGN stock a great bargain. Regeneron's return on equity is 28%. Its price-to-earnings ratio is below 16, with investors paying $333 for over $21 per share of earnings. That's bargain territory.Regeneron is expected to earn $5.39 per share on revenues of $1.72 billion when it next reports May 7, but it has lately made a habit of beating earnings estimates, often by a lot. Analysts are whispering it might beat estimates this quarter by 14 cents, but in the last quarter, it beat estimates by $1.24, and the current estimates are lower. The Bottom Line on Regeneron StockI take a long-term view on stocks, looking for the leading edge of technology, where the value added to society is greatest.The current decade has been all about the cloud, which has brought enormous amounts of computing power to desktops and even mobile platforms.The next decade will be about using this power to turn DNA into a computer language that can be read and manipulated. A research methodology can act like an old-style PC operating system in this worldThis is not a guarantee of long-term success. It only means a company is playing the new game in the right way. That's what I like about Regeneron stock. It has method amid the madness.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in REGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post This Is Why You Shouldn't Count Regeneron Stock Out appeared first on InvestorPlace.

  • Top Gene-Sequencing Stocks for 2019
    Motley Fool6 days ago

    Top Gene-Sequencing Stocks for 2019

    These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

  • Cambridge's bluebird bio expanding Kendall Square HQ
    American City Business Journals7 days ago

    Cambridge's bluebird bio expanding Kendall Square HQ

    The gene therapy company plans to expand into office and lab space directly adjacent to its current headquarters.

  • Here's Why Shares of bluebird bio Slumped Today
    Motley Fool8 days ago

    Here's Why Shares of bluebird bio Slumped Today

    No-news anxiety-selling seems to be to blame for the biotech's woes.

  • ETF Trends10 days ago

    Four Companies Could Power The New Genomics ETF

    Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...

  • Motley Fool16 days ago

    Why bluebird bio Could Deliver Miracles to Genetic Disease Patients

    CAR-T therapies have the potential to work wonders in hospitals and in your portfolio.

  • Markit16 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for BLUE with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BLUE is favorable, with net inflows of $114.61 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Motley Fool16 days ago

    5 Stocks in the Age of Miracles

    Motley Fool co-founder David Gardner shares five picks that are changing the world and bringing tomorrow closer to today.

  • Celgene & Acceleron Submit BLA for Luspatercept to the FDA
    Zacks17 days ago

    Celgene & Acceleron Submit BLA for Luspatercept to the FDA

    Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.

  • 3 High-Growth Genomics Stocks You Can Buy
    Motley Fool18 days ago

    3 High-Growth Genomics Stocks You Can Buy

    These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.

  • 2 Blockbuster Gene Therapy Programs to Watch in 2019
    Motley Fool25 days ago

    2 Blockbuster Gene Therapy Programs to Watch in 2019

    A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.

  • Most Analysts Have Given bluebird bio Positive Ratings in March
    Market Realist27 days ago

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing

  • Reuters27 days ago

    EMA panel recommends approval of Bluebird Bio's first gene therapy

    A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod. Final approval depends on the European Commission, which generally follows recommendations from the Committee on Human Medicinal Products (CHMP). Zynteglo is intended for patients 12 years and older who need regular blood transfusions to manage their disease and have no matching donor for a stem cell transplant, CHMP said https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019.

  • Business Wire27 days ago

    bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

    bluebird bio, Inc. (BLUE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q-globin gene), a gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. If approved, ZYNTEGLO, formerly referred to as LentiGlobin™ for TDT, will be the first gene therapy to treat TDT.

  • Celgene (CELG) Submits NDA for MS Drug to FDA for Review
    Zackslast month

    Celgene (CELG) Submits NDA for MS Drug to FDA for Review

    Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

  • Massachusetts concern details plan to hire new workers in Durham
    American City Business Journalslast month

    Massachusetts concern details plan to hire new workers in Durham

    With the cut the cut of a ribbon this morning, Massachusetts-based Bluebird Bio's newest manufacturing family in RTP is operational – but its CEO says says more growth is already expected.

  • Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?
    Zackslast month

    Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?

    Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.